O	0	1	A
O	2	12	randomized
O	13	18	phase
O	19	21	II
O	22	33	presurgical
O	34	39	trial
O	40	42	of
B-intervention	43	54	transdermal
I-intervention	55	56	4
I-intervention	56	57	-
I-intervention	57	73	hydroxytamoxifen
I-intervention	74	77	gel
O	78	84	versus
O	85	89	oral
B-control	90	99	tamoxifen
O	100	102	in
O	103	108	women
O	109	113	with
O	114	120	ductal
O	121	130	carcinoma
O	131	133	in
O	134	138	situ
O	139	141	of
O	142	145	the
O	146	152	breast
O	152	153	.

O	154	159	Local
O	160	171	transdermal
O	172	179	therapy
O	180	182	to
O	183	186	the
O	187	193	breast
O	194	197	may
O	198	205	achieve
O	206	215	effective
O	216	222	target
O	222	223	-
O	223	228	organ
O	229	233	drug
O	234	242	delivery
O	242	243	,
O	244	249	while
O	250	261	diminishing
O	262	270	systemic
O	271	278	effects
O	278	279	.

O	280	282	We
O	283	292	conducted
O	293	294	a
O	295	305	randomized
O	305	306	,
O	307	313	double
O	313	314	-
O	314	319	blind
O	319	320	,
O	321	328	placebo
O	328	329	-
O	329	339	controlled
O	340	345	phase
O	346	348	II
O	349	354	trial
O	355	364	comparing
O	365	376	transdermal
O	377	378	4
O	378	379	-
O	379	395	hydroxytamoxifen
O	396	399	gel
O	400	401	(
O	401	402	4
O	402	403	-
O	403	406	OHT
O	406	407	)
O	408	410	to
O	411	415	oral
O	416	425	tamoxifen
O	426	427	(
O	427	431	oral
O	431	432	-
O	432	433	T
O	433	434	)
O	435	437	in
O	438	443	women
O	444	448	with
O	449	455	ductal
O	456	465	carcinoma
O	466	468	in
O	469	473	situ
O	474	475	(
O	475	479	DCIS
O	479	480	)
O	480	481	.

B-total-participants	482	488	Twenty
I-total-participants	488	489	-
I-total-participants	489	494	seven
B-eligibility	495	498	pre
I-eligibility	498	499	-
I-eligibility	500	503	and
I-eligibility	504	518	postmenopausal
I-eligibility	519	524	women
O	525	529	were
O	530	540	randomized
O	541	543	to
O	544	545	4
O	545	546	-
O	546	549	OHT
O	550	551	(
O	551	552	4
O	553	555	mg
O	555	556	/
O	556	559	day
O	559	560	)
O	561	563	or
O	564	568	oral
O	568	569	-
O	569	570	T
O	571	572	(
O	572	574	20
O	575	577	mg
O	577	578	/
O	578	581	day
O	581	582	)
O	583	586	for
O	587	588	6
O	589	591	to
O	592	594	10
O	595	600	weeks
O	601	607	before
O	608	615	surgery
O	615	616	.

O	617	623	Plasma
O	623	624	,
O	625	631	nipple
O	632	640	aspirate
O	641	646	fluid
O	646	647	,
O	648	651	and
O	652	658	breast
O	659	666	adipose
O	667	673	tissue
O	674	688	concentrations
O	689	691	of
O	692	701	tamoxifen
O	702	705	and
O	706	709	its
O	710	715	major
O	716	727	metabolites
O	728	732	were
O	733	743	determined
O	744	746	by
O	747	753	liquid
O	754	768	chromatography
O	768	769	/
O	769	775	tandem
O	776	780	mass
O	781	793	spectrometry
O	793	794	.

O	795	798	The
O	799	806	primary
O	807	815	endpoint
O	816	819	was
B-outcome-Measure	820	824	Ki67
I-outcome-Measure	825	833	labeling
I-outcome-Measure	834	836	in
I-outcome-Measure	837	841	DCIS
I-outcome-Measure	842	849	lesions
O	849	850	,
O	851	859	measured
O	860	862	by
O	863	883	immunohistochemistry
O	883	884	.

O	885	887	In
O	888	894	plasma
O	894	895	,
B-outcome-Measure	896	903	insulin
I-outcome-Measure	903	904	-
I-outcome-Measure	904	908	like
I-outcome-Measure	909	915	growth
I-outcome-Measure	916	922	factor
I-outcome-Measure	922	923	-
I-outcome-Measure	923	924	1
I-outcome-Measure	925	926	(
I-outcome-Measure	926	930	IGFI
I-outcome-Measure	930	931	)
I-outcome-Measure	931	932	,
I-outcome-Measure	933	936	sex
I-outcome-Measure	937	944	hormone
I-outcome-Measure	944	945	-
I-outcome-Measure	945	952	binding
I-outcome-Measure	953	961	globulin
I-outcome-Measure	962	963	(
I-outcome-Measure	963	967	SHBG
I-outcome-Measure	967	968	)
O	968	969	,
O	970	973	and
B-outcome-Measure	974	985	coagulation
I-outcome-Measure	986	993	protein
I-outcome-Measure	994	1008	concentrations
O	1009	1013	were
O	1014	1024	determined
O	1024	1025	.

B-outcome	1026	1037	Posttherapy
I-outcome	1038	1042	Ki67
I-outcome	1043	1052	decreased
O	1053	1055	by
B-iv-cont-mean	1056	1057	3
I-iv-cont-mean	1057	1058	.
I-iv-cont-mean	1058	1059	4
I-iv-cont-mean	1059	1060	%
O	1061	1063	in
O	1064	1067	the
O	1068	1069	4
O	1069	1070	-
O	1070	1073	OHT
O	1074	1077	and
B-cv-cont-mean	1078	1079	5
I-cv-cont-mean	1079	1080	.
I-cv-cont-mean	1080	1081	1
I-cv-cont-mean	1081	1082	%
O	1083	1085	in
O	1086	1089	the
O	1090	1094	oral
O	1094	1095	-
O	1095	1096	T
O	1097	1102	group
O	1103	1104	(
O	1104	1105	P
O	1106	1107	â‰¤
O	1108	1109	0
O	1109	1110	.
O	1110	1112	03
O	1113	1115	in
O	1116	1120	both
O	1120	1121	,
O	1122	1129	between
O	1129	1130	-
O	1130	1135	group
O	1136	1137	P
O	1138	1139	=
O	1140	1141	0
O	1141	1142	.
O	1143	1145	99
O	1145	1146	)
O	1146	1147	.

B-outcome	1148	1152	Mean
I-outcome	1153	1159	plasma
I-outcome	1160	1161	4
I-outcome	1161	1162	-
I-outcome	1162	1165	OHT
O	1166	1169	was
B-iv-cont-mean	1170	1171	0
I-iv-cont-mean	1171	1172	.
I-iv-cont-mean	1172	1173	2
O	1174	1177	and
B-cv-cont-mean	1178	1179	1
I-cv-cont-mean	1179	1180	.
I-cv-cont-mean	1180	1181	1
I-cv-cont-mean	1182	1184	ng
I-cv-cont-mean	1184	1185	/
I-cv-cont-mean	1185	1187	mL
O	1188	1190	in
O	1191	1192	4
O	1192	1193	-
O	1193	1196	OHT
O	1197	1200	and
O	1201	1205	oral
O	1206	1212	groups
O	1212	1213	,
O	1214	1226	respectively
O	1227	1228	(
O	1228	1229	P
O	1230	1231	=
O	1232	1233	0
O	1233	1234	.
O	1234	1238	0003
O	1238	1239	)
O	1239	1240	,
O	1241	1248	whereas
B-outcome	1249	1253	mean
I-outcome	1254	1260	breast
I-outcome	1261	1268	adipose
I-outcome	1269	1275	tissue
I-outcome	1276	1290	concentrations
I-outcome	1291	1293	of
I-outcome	1294	1295	4
I-outcome	1295	1296	-
I-outcome	1296	1299	OHT
O	1300	1304	were
B-iv-cont-mean	1305	1306	5
I-iv-cont-mean	1306	1307	.
I-iv-cont-mean	1307	1308	8
I-iv-cont-mean	1309	1311	ng
I-iv-cont-mean	1311	1312	/
I-iv-cont-mean	1312	1313	g
O	1314	1316	in
O	1317	1320	the
O	1321	1322	4
O	1322	1323	-
O	1323	1326	OHT
O	1327	1332	group
O	1333	1336	and
B-cv-cont-mean	1337	1338	5
I-cv-cont-mean	1338	1339	.
I-cv-cont-mean	1339	1340	4
I-cv-cont-mean	1341	1343	ng
I-cv-cont-mean	1343	1344	/
I-cv-cont-mean	1344	1345	g
O	1346	1348	in
O	1349	1352	the
O	1353	1357	oral
O	1358	1363	group
O	1364	1365	(
O	1365	1366	P
O	1367	1368	=
O	1369	1370	0
O	1370	1371	.
O	1371	1373	88
O	1373	1374	)
O	1374	1375	.

O	1376	1381	There
O	1382	1386	were
O	1387	1398	significant
O	1399	1408	increases
O	1409	1411	in
B-outcome	1412	1418	plasma
I-outcome	1419	1423	SHBG
O	1423	1424	,
B-outcome	1425	1431	factor
I-outcome	1432	1436	VIII
O	1436	1437	,
O	1438	1441	and
B-outcome	1442	1445	von
I-outcome	1446	1456	Willebrand
I-outcome	1457	1463	factor
O	1464	1467	and
O	1468	1469	a
O	1470	1481	significant
O	1482	1490	decrease
O	1491	1493	in
B-outcome	1494	1500	plasma
I-outcome	1501	1505	IGFI
I-outcome	1506	1510	with
I-outcome	1511	1515	oral
I-outcome	1515	1516	-
I-outcome	1516	1517	T
O	1517	1518	,
O	1519	1522	but
O	1523	1526	not
O	1527	1531	with
O	1532	1533	4
O	1533	1534	-
O	1534	1537	OHT
O	1537	1538	.

O	1539	1542	The
O	1543	1552	incidence
O	1553	1555	of
B-outcome	1556	1559	hot
I-outcome	1560	1567	flashes
O	1568	1571	was
O	1572	1579	similar
O	1580	1582	in
O	1583	1587	both
O	1588	1594	groups
O	1594	1595	.

O	1596	1599	The
O	1600	1617	antiproliferative
O	1618	1624	effect
O	1625	1627	of
O	1628	1629	4
O	1629	1630	-
O	1630	1633	OHT
O	1634	1637	gel
O	1638	1645	applied
O	1646	1648	to
O	1649	1655	breast
O	1656	1660	skin
O	1661	1664	was
O	1665	1672	similar
O	1673	1675	to
O	1676	1680	that
O	1681	1683	of
O	1684	1688	oral
O	1688	1689	-
O	1689	1690	T
O	1690	1691	,
O	1692	1695	but
O	1696	1703	effects
O	1704	1706	on
O	1707	1716	endocrine
O	1717	1720	and
O	1721	1732	coagulation
O	1733	1743	parameters
O	1744	1748	were
O	1749	1756	reduced
O	1756	1757	.

O	1758	1763	These
O	1764	1772	findings
O	1773	1780	support
O	1781	1784	the
O	1785	1792	further
O	1793	1803	evaluation
O	1804	1806	of
O	1807	1812	local
O	1813	1824	transdermal
O	1825	1832	therapy
O	1833	1836	for
O	1837	1841	DCIS
O	1842	1845	and
O	1846	1852	breast
O	1853	1859	cancer
O	1860	1870	prevention
O	1870	1871	.
